Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?

References

• Yang CJ, Hung JY, Tsai MJ, et al. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy. BMC Pharmacol Toxicol. 2017;18(1):21. doi:10.1186/s40360-017-0130-0
   PubMedGoogle Scholar
• Planchard D, Janne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389(21):1935–1948. doi:10.1056/NEJMoa2306434
   PubMed Web of Science ®Google Scholar
• Cho BC, Felip E, Hayashi H, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus Osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022;18(6):639–647. doi:10.2217/fon-2021-0923
   PubMed Web of Science ®Google Scholar
• Cho BC, Felip E, Spira A, et al. Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced NSCLC: primary results from MARIPOSA, a Phase 3, global, randomized, controlled trial. ESMO Congress Oct; Madrid, Spain; 2023.
   Google Scholar
• Yang JC, Lee DH, Lee JS, et al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE-789 study. J Clin Oncol. 2023;17(41):abstrLBA9000.
   Google Scholar
• Mok T, Nakagawa K, Park K, et al. Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of checkMate 722. J Clin Oncol. 2024;2:JCO2301017.
   Google Scholar
• Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023;11(7):624–636. doi:10.1016/S2213-2600(23)00135-2
   PubMed Web of Science ®Google Scholar
• Chen G. IMpower151: phase III study of atezolizumab+bevacizumab+ chemotherapy in first-line metastatic nonsquamous NSCLC. Presented at: 2023 IASLC World Conference on Lung Cancer. Republic of Singapore, Singapore; 2023.
   Google Scholar
• Scharpenseel H, Hanssen A, Loges S, et al. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Sci Rep. 2019;9(1):7406. doi:10.1038/s41598-019-43678-6
   PubMedGoogle Scholar
• Janne PA, Baik C, Su WC, et al. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov. 2022;12(1):74–89. doi:10.1158/2159-8290.CD-21-0715
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Tanizaki J, Maenishi O, et al. HER3 augmentation via Blockade of EGFR/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non-small cell lung cancer. Clin Cancer Res. 2022;28(2):390–403. doi:10.1158/1078-0432.CCR-21-3359
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Hirotani K, Kawakami H, et al. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib. Oncogene. 2016;35(7):878–886. doi:10.1038/onc.2015.142
   PubMed Web of Science ®Google Scholar
• Haikala HM, Janne PA. Thirty Years of HER3: from basic biology to therapeutic interventions. Clin Cancer Res. 2021;27(13):3528–3539. doi:10.1158/1078-0432.CCR-20-4465
   PubMed Web of Science ®Google Scholar
• Kawakami H, Yonesaka K. HER3 and its ligand, heregulin, as targets for cancer therapy. Recent Pat Anticancer Drug Discov. 2016;11(3):267–274. doi:10.2174/1574892811666160418123221
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–1043. doi:10.1126/science.1141478
   PubMed Web of Science ®Google Scholar
• Yu HA, Goto Y, Hayashi H, et al. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;41(35):5363–5375. doi:10.1200/JCO.23.01476
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Cheng Y, Zhou C, Mechanisms of acquired resistance to first-line Osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:740.
   Google Scholar
• Ge M, Zhuang Y, Zhou X, Huang R, Liang X, Zhan Q. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases. J Neurooncol. 2017;135(2):413–418. doi:10.1007/s11060-017-2590-x
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Park YH, Yamashita T, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 Subgroup Analysis. Cancer Discov. 2022;12(12):2754–2762. doi:10.1158/2159-8290.CD-22-0837
   PubMed Web of Science ®Google Scholar
• Mok T, Janne PA, Nishio M, et al. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. Future Oncol. 2023. doi:10.2217/fon-2023-0602
   PubMed Web of Science ®Google Scholar
• Haikala HM, Lopez T, Kohler J, et al. EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody-drug conjugate HER3-DXd. Cancer Res. 2022;82(1):130–141. doi:10.1158/0008-5472.CAN-21-2426
   PubMed Web of Science ®Google Scholar
• A phase 1 open-label study of patritumab deruxtecan in combination with osimertinib in subjects with locally advanced or metastatic EGFR-mutated non-small cell lung cancer. Report No.: NCT04676477; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04676477. Accessed July 3, 2024.
   Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742. doi:10.1016/S1470-2045(11)70184-X
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of Afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334. doi:10.1200/JCO.2012.44.2806
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Yun J, Hong MH, Kim SY, et al. YH25448, an Irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer. Clin Cancer Res. 2019;25(8):2575–2587. doi:10.1158/1078-0432.CCR-18-2906
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Han JY, Lee KH, et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study. Lancet Oncol. 2019;20(12):1681–1690. doi:10.1016/S1470-2045(19)30504-2
   PubMed Web of Science ®Google Scholar
• Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR and cMet Is Effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76(13):3942–3953. doi:10.1158/0008-5472.CAN-15-2833
   PubMed Web of Science ®Google Scholar
• Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther. 2020;19(10):2044–2056. doi:10.1158/1535-7163.MCT-20-0071
   PubMed Web of Science ®Google Scholar
• Yun J, Lee SH, Kim SY, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR Exon 20 insertion-driven NSCLC. Cancer Discov. 2020;10(8):1194–1209. doi:10.1158/2159-8290.CD-20-0116
   PubMed Web of Science ®Google Scholar
• Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on Osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2023;34:S1307. doi:10.1016/j.annonc.2023.10.063
   Web of Science ®Google Scholar